Riegel v. Medtronic, Inc.

Riegel v. Medtronic, Inc.
Case name	Riegel v. Medtronic, Inc.
Citation	552 U.S. 312 (2008)
Court	Supreme Court of the United States
Decided	June 18, 2008
Docket	No. 06-179
Majority	Scalia
Joinmajority	Roberts, Stevens, Kennedy, Thomas, Breyer, Alito
Concurrence	Stevens (in part)
Dissent	Souter
Laws applied	Federal Food, Drug, and Cosmetic Act

Riegel v. Medtronic, Inc. was a landmark 2008 decision of the Supreme Court of the United States addressing preemption under the Federal Food, Drug, and Cosmetic Act for medical devices regulated through the Food and Drug Administration's premarket approval process. The Court held that state-law claims challenging the safety and labeling of a medical device approved by the Food and Drug Administration were preempted, affecting litigation strategy for plaintiffs, manufacturers, and regulators across the United States.

Background

The case arose amid ongoing tensions between federal regulatory authority vested in the Food and Drug Administration and state tort remedies such as product liability suits brought under state common law and statute. Debates over preemption had featured in earlier decisions including Medtronic, Inc. v. Lohr and informed interactions among stakeholders such as medical device manufacturers, patient advocacy groups, insurance carriers, and members of the United States Congress. The legal framework centered on the Federal Food, Drug, and Cosmetic Act and its preemption clause as interpreted in administrative and judicial contexts including disputes over the scope of premarket approval and the distinctions drawn by statutes, regulations, and agency guidance.

Facts of the Case

Respondent patients alleged that a percutaneous transluminal coronary angioplasty balloon catheter, manufactured by petitioner and approved through the Food and Drug Administration's premarket approval (PMA) process, ruptured during use, causing serious injury. Plaintiffs filed state-law claims in a New York trial court alleging negligence, strict liability, and failure to warn against the manufacturer, invoking remedies available under New York state tort law and analogous common-law doctrines. The manufacturer countered that the device's PMA approval, together with express federal requirements, precluded state-law suits that would impose requirements different from or additional to federal specifications.

Legal Proceedings and Questions Presented

After trial and appellate proceedings in state courts and the United States Court of Appeals for the Second Circuit, which addressed whether federal approval foreclosed state-law claims, the case reached the Supreme Court of the United States. The central questions presented were whether the Federal Food, Drug, and Cosmetic Act's preemption provision barred state common-law claims challenging the safety and labeling of a medical device that had received PMA from the Food and Drug Administration, and how to reconcile this with prior Supreme Court decisions such as Medtronic, Inc. v. Lohr and statutory interpretations in related cases like Wyeth v. Levine.

Supreme Court Decision

In a majority opinion authored by Antonin Scalia, the Supreme Court of the United States held that the PMA process imposes specific federal requirements and that state-law claims seeking to enforce different or additional requirements are preempted by the Federal Food, Drug, and Cosmetic Act. The Court concluded that allowing state tort suits would conflict with the federal regulatory scheme administered by the Food and Drug Administration and thus were displaced. Justice David Souter filed a dissent arguing for a different reading of the statutory language and congressional intent regarding preemption.

Rationale and Legal Reasoning

The majority relied on statutory text, precedent, and administrative practice, distinguishing devices cleared through the 510(k) process from those approved via PMA; the former were previously addressed in Medtronic, Inc. v. Lohr, while the latter received more exacting federal scrutiny. The Court analyzed whether state-law claims amounted to requirements "different from, or in addition to" federal requirements, applying principles from cases addressing congressional intent and federal supremacy such as Rice v. Santa Fe Elevator Corp. and interpreting the Federal Food, Drug, and Cosmetic Act's express preemption clause. The opinion emphasized deference to the centralized federal regulatory regime overseen by the Food and Drug Administration and treated PMA as establishing fixed federal standards that conflicted with varying state-law obligations. Justice John Paul Stevens concurred in part while expressing reservations about the decision's scope; Justice Stephen Breyer joined the judgment but had distinct views on statutory construction.

Impact and Subsequent Developments

The decision constrained state-law remedies for injuries allegedly caused by FDA-approved medical devices, prompting legislative responses in the United States Congress, renewed litigation strategies in federal and state courts, and scholarly debate in journals focusing on tort law, regulatory policy, and health law. Litigation shifted toward claims alleging violations of federal requirements or defects in the approval process, while patient-advocacy organizations and some state attorneys general sought alternative avenues for consumer protection. Subsequent cases and commentaries revisited the balance between federal preemption and state tort law, including analysis in the wake of Wyeth v. Levine, administrative actions by the Food and Drug Administration, and proposed statutory amendments to clarify preemption for medical devices and pharmaceuticals. The ruling remains pivotal for manufacturers such as Medtronic, trial lawyers, insurers, regulators, and policymakers engaged with healthcare regulation, product safety, and civil remedies.

Category:2008 in United States case law Category:Supreme Court of the United States cases Category:United States federal preemption case law